2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Abbott agreed to resolve the Gill lawsuit and necrotizing enterocolitis claims for about 2,000 other infants for an aggregate of approximately $670 million, instead of continuing its appeal or paying about $600 million on the Gill judgment plus interest. The company states the agreements are a compromise and not an admission of liability, but the payment is a sizable cost, and roughly 1,700 lawsuits involving about 12,700 infants remain pending.
Gill case: July 2024 Missouri jury verdict of $495 million, affirmed by the Missouri Court of Appeals in May 2026.
Settlement: aggregate amount of approximately $670 million covering the Gill case and claims for about 2,000 additional infants.
Alternative cited: paying approximately $600 million, the Gill judgment plus accrued interest to date.
Remaining litigation: roughly 1,700 lawsuits involving claims for about 12,700 individual infants.
RenovoRx said Nasdaq confirmed on August 20, 2026 that it has regained compliance with the Nasdaq minimum bid price requirement, and Nasdaq considers the matter closed. The closing bid price was at or above $1.00 per share for the ten consecutive business days from August 6 through August 19, 2026. The filing removes a listing deficiency that had been pending since December 31, 2025, but it reports no financial results or business changes.
Nasdaq notified RenovoRx on December 31, 2025 that its stock had closed below $1.00 for 30 consecutive business days.
Nasdaq confirmed on August 20, 2026 that the closing bid price was $1.00 or greater for ten consecutive business days, August 6 through August 19, 2026.
Nasdaq considers the minimum bid price matter closed; the filing reports no financial results or other business developments.
Nasdaq notified BullFrog AI Holdings that it is eligible for a second 180-day period, until February 8, 2027, to regain the $1.00 minimum closing bid price, which the company has not yet met. The company plans to effect a reverse stock split before the period ends if the price is not cured organically, and failure to regain compliance would make its listed securities subject to delisting.
Nasdaq notice dated August 18, 2026; the first compliance period ended August 10, 2026.
Second Compliance Period runs until February 8, 2027; compliance requires at least $1.00 closing bid for a minimum of 10 consecutive business days.
Stockholders approved in October 2025 a reverse stock split ratio between 1-to-2 and 1-to-15, to be set by the Board.
The company states there is no assurance it will regain compliance during the period.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.